Back

Beta-blocker dose titration, functional capacity, and all-cause mortality in patients with heart failure and reduced ejection fraction

29 August 2026 (15:15 - 16:00)
Organised by: Logo
Congress Presentation Part of: Heart failure: balancing titration and renal function Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Kristian Berge

Akershus University Hospital - AHUS, Nordbyhagen (Norway)

7 More presentations in this session

Presentation thumbnail
How do we treat patients with chronic kidney disease stages 4-5 and heart failure with reduced left ventricular ejection fraction? Impact on 1-year mortality and hospital admissions
Doctor M. Anguita Gamez (Madrid, ES)
Abstract Slides
Presentation thumbnail
Association between up-titration of guideline-directed medical therapy and clinical outcomes in patients with chronic heart failure with reduced ejection fraction
Doctor Y. Agata (Sapporo, JP)
Abstract Slides
Presentation thumbnail
Sector-level disparities in ESC-recommended GDMT implementation for patients with HFrEF: a real-world retrospective comparative study
Miss R. Niraula (Kobuleti, GE)
Abstract Slides
Presentation thumbnail
Sex-related differences in contemporary HFrEF management: insights from the Italian OpTIMa-HF Registry
Doctor F. Marzano (Naples, IT)
Abstract Slides
Presentation thumbnail
The effect of left bundle branch block on pharmacotherapy and changes of left ventricular ejection fraction after the rapid-up titration of guideline-directed medical therapy in heart failure
Doctor P. Schaffer (Budapest, HU)
Abstract Slides

Access the full session

Session thumbnail
Heart failure: balancing titration and renal function

The Event

Event poster

ESC Congress 2026

29 August 2026 15:15 CET
You may be interested in
thumbnail
Congress Presentation
Prognostic importance of changes in 6-min walk test during titration of pharmacotherapy in HFrEF
21 May 2023
thumbnail
Congress Presentation
Beta-blocker exposure and long-term survival in patients with transthyretin amyloid cardiomyopathy.
27 August 2021
thumbnail
Congress Presentation
How much physical activity and sitting should women with heart disease do to reduce their risk of death?: :a cohort mortality survival tree analysis
13 June 2025
thumbnail
Congress Presentation
Target dose of heart failure medications is associated with better mortality/morbidity: data from the Swedish Heart Failure Registry
29 June 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources